Esra Arslan Ateş

Esra Arslan Ateş

Auto-generated profile, based on publicly available information

Esra Arslan Ateş

Department of Medical Genetics, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
EAEsra Arslan Ateş
Esra Arslan Ateş
ATAyberk Türkyilmaz
Ayberk Türkyilmaz
ÖYÖzlem Yıldırım
Özlem Yıldırım
CACeren Alavanda
Ceren Alavanda
HPHamza Polat
Hamza Polat
AAAhmet Arman
Ahmet Arman

17 May 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
SKSare Betul Kaygusuz
Sare Betul Kaygusuz
EAEsra Arslan Ates
Esra Arslan Ates
MVMaria Lillina Vignola
Maria Lillina Vignola
BVBurcu Volkan
Burcu Volkan
BGBilgen Bilge Geckinli
Bilgen Bilge Geckinli
TGTulay Guran
Tulay Guran
Context Developmental disorders of the pituitary gland leading to congenital hypopituitarism can either be isolated or associated with extrapituitary abnormalities (syndromic hypopituitarism). A large number of syndromic hypopituitarism cases are linked to mutations in transcription factors. The forkhead box A2 (FOXA2) is a transcription factor that plays a key role in the central nervous system, foregut, and pancreatic development. Objective This work aims to characterize 2 patients with syndromic hypopituitarism due to FOXA2 gene defects. Results We report a novel heterozygous nonsense c.616C > T(p.Q206X) variant that leads to a truncated protein that lacks part of the DNA-binding domain of FOXA2, resulting in impaired transcriptional activation of the glucose transporter type 2 (GLUT2)-luciferase reporter. The patient is the sixth patient described in the literature with a FOXA2 mutation, and the first patient exhibiting pancreatic hypoplasia. We also report a second patient with a novel de novo 8.53 Mb deletion of 20p11.2 that encompasses FOXA2, who developed diabetes mellitus that responded to sulfonylurea treatment. Conclusion Our 2 cases broaden the molecular and clinical spectrum of FOXA2-related disease, reporting the first nonsense mutation and the first case of pancreatic dysgenesis.

23 June 2022 in Medeniyet Medical Journal
Verified
Journal Article
Open access
EAEsra Arslan Ates
Esra Arslan Ates
ATAyberk Turkyilmaz
Ayberk Turkyilmaz
CACeren Alavanda
Ceren Alavanda
OYOzlem Yildirim
Ozlem Yildirim
AGAhmet Ilter Guney
Ahmet Ilter Guney
Hereditary cancer syndromes (HCSs) are a heterogenous group of disorders caused by germline pathogenic variations in various genes that function in cell growth and proliferation. This study aimed to describe the germline variations in patients with hereditary cancer using multigene panels. The molecular and clinical findings of 218 patients with HCS were evaluated. In addition, 25 HCS-related genes were sequenced using a multigene panel, and variations were classified according to the American College of Medical Genetics and Genomics (ACMG) criteria. In total, 218 HCS patients predominantly with breast, colorectal, ovarian, gastric, and endometrium cancers were included. Pathogenic variations in 12 distinct genes were detected in 36 of 218 (16.5%) cases. In this study, the most affected gene was the ATM gene, in which pathogenic variations were detected in 8 of 218 cases, followed by CHEK2 (3.2%), MUTYH (3.2%), BRIP1 (1.8%), BARD1 (0.9%), TP53 (0.9%), PALB2 (0.4%), MLH1 (0.4%), MSH2 (0.4%), PMS2 (0.4%), RAD50 (0.4%), and RAD51C (0.4%). This study contributes to genotype-phenotype correlation in HCSs and expands the variation spectrum by introducing three novel pathogenic variations. The wide spectrum of the gene pathogenic variations detected and the presence of multiple gene defects in the same patient make the multigene panel testing a valuable tool in detecting the hereditary forms of cancer and providing effective genetic counseling and family specific screening strategies.

13 January 2023 in Molecular Syndromology
Verified
Journal Article
Open access
PDF file
ŞDŞenol Demir
Şenol Demir
CACeren Alavanda
Ceren Alavanda
GYGözde Yeşil
Gözde Yeşil
AAAyça Dilruba Aslanger
Ayça Dilruba Aslanger
EAEsra Arslan Ateş
Esra Arslan Ateş
Introduction: Myhre syndrome (MS; OMIM #139210) is a rare connective tissue disorder presenting with cardiovascular, respiratory, gastrointestinal, and skeletal system findings. Fewer than 100 patients were reported until recently, and all molecularly confirmed cases had de novo heterozygous gain-of-function mutations in the SMAD4 gene. Dysregulation of the TGF-beta signaling pathway leads to axial and appendicular skeleton, connective tissue, cardiovascular system, and central nervous system abnormalities. Case Presentation: Two siblings, 12 and 9 years old, were referred to us because of intellectual disability, neurodevelopmental delay, and dysmorphic facial features. Physical examination revealed hypertelorism, strabismus, small mouth, prognathism, short neck, stiff skin, and brachydactyly. Discussion: With a clinical diagnosis of MS, the SMAD4 gene was analyzed via Sanger sequencing, and a heterozygous c.1486C>T (p.Arg496Cys) pathogenic variation was detected in both of the siblings. The segregation analysis revealed that the mutation was inherited from the father who displayed a milder phenotype. Among the 90 patients in the literature, one family was reported in which two siblings carried the same variation (p.Arg496Cys), inherited from the severely affected mother. We are reporting the second family which has three affected family members, a father and two children. We report this study to remind the clinicians to be aware of the parental transmission of SMAD4 variations and also evaluate the parents of the Myhre cases.

22 September 2021 in Balkan Medical Journal
Verified
Journal Article
Open access
EAEsra Arslan Ates
Esra Arslan Ates
OUOzlem Ustay
Ozlem Ustay
HPHamza Polat
Hamza Polat
TATugce Apaydin
Tugce Apaydin
OEOnur Elbasan
Onur Elbasan
AGAhmet Ilter Guney
Ahmet Ilter Guney
Maturity-onset diabetes of the young (MODY) is a rare monogenic type of diabetes, and accounts for 2-5% of all diabetes cases. An early age of onset, a family history supporting autosomal-dominant inheritance, insulin resistance, and the absence of autoimmunity are the major characteristics of MODY. However, genetic testing is crucial for diagnosis. To investigate the 7 MODY-related genes and clinical findings of patients with a preliminary clinical diagnosis of MODY. Retrospective cross-sectional study. In this study, 7 genes (KCNJ11, ABCC8, INS, GCK, HNF4A, HNF1A, and HNF1B) related to MODY were screened via targeted sequencing in 182 cases with a confirmed pre-diagnosis of MODY. The clinical characteristics of the patients were evaluated retrospectively. A total of 182 patients, 48% of whom were women, between the ages of 18-62 were included in the study. In 30 cases (16.4%), 28 different pathogenic variations were found, of which 20 were previously reported and 8 were novel variations segregated by disease within the family. Pathogenic variations were detected in the following genes in order of mutation frequency; GCK, HNF1A, ABCC8, HNF4A, HNF1B and KCNJ11. Interestingly, six of the 30 cases (20%) carried a pathogenic variation in the ABCC8 gene. No mutation was detected in the INS gene. A family history of vertically transmitted diabetes and elevated HbA1C at the time of diagnosis were found in 20 (66%) and 16 (52%) cases, respectively. In this series, 28 different pathogenic variations are ­identified, 8 of which are novel. The rate of pathogenic variation in the ABCC8 gene is unexpectedly high. Two-thirds of cases have a family history of vertically transmitted diabetes.

12 July 2024 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
EVEva Vanbelleghem
Eva Vanbelleghem
TDTim Van Damme
Tim Van Damme
ABAude Beyens
Aude Beyens
SSSofie Symoens
Sofie Symoens
Kathleen ClaesKathleen Claes
Kathleen Claes
BCBert Callewaert
Bert Callewaert